This review highlights that while oxidative stress plays a key role in cardiac dysfunction in metabolic syndrome, large-scale clinical trials of antioxidant therapies have so far lacked efficacy and shown undesired side effects.
No takes yet. Share an insight, caveat, or question.
Antioxidant therapies should not be pursued for CVD; leaves open whether targeted redox modulation can mitigate cardiac dysfunction in metabolic syndrome.
Ilkun et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: